GlobalData’s report, “Immunochemistry Analyzers Market Forecast to 2033,” reveals that India’s CLA analysers market accounted for only around 2 per cent of the Asia-Pacific market in 2023
Chemiluminescence immunoassay (CLIA) analysers are indispensable tools in Indian medical landscape, offering a broad spectrum of applications encompassing infectious disease testing and cancer biomarker analysis. Consequently, they play a pivotal role in enhancing healthcare delivery, facilitating disease management, and advancing public health initiatives in the country. Against this backdrop, India’s CLA analysers market is expected to grow at a compound annual growth rate (CAGR) of around 6 per cent through 2033, forecasts GlobalData.
GlobalData’s report, “Immunochemistry Analyzers Market Forecast to 2033,” reveals that India’s CLA analysers market accounted for only around 2 per cent of the Asia-Pacific market in 2023.
Strengthening the global foothold of Indian diagnostic companies in the CLIA analyser segment necessitates strategic initiatives such as fostering international collaborations, which can enhance their presence and competitiveness.
Recently, Japan-based Fujirebio Inc and India-based Agappe Diagnostics have entered into an agreement of contract development and manufacturing organisation (CDMO) partnership for cartridge-based CLIA system reagents manufacturing project for the immunology equipment Mispa i60 and Mispa i121. While Fujirebio will supply equipment and raw materials, Agappe will develop and manufacture dedicated reagents, meeting regulatory standards.
Shreya Jain, Medical Devices Analyst, GlobalData comments, “Despite the limitations including technology dependency, limited R&D investment and market competition, India’s cost-effective manufacturing capabilities stemming from lower labor and operational expenses underscore its appeal as a manufacturing hub. By combining the mutually complementary strengths of both companies, Agappe and Fujirebio can deliver high-quality CLIA solutions with cost competitiveness, contributing to healthcare advancement in India.”
Agappe and Fujirebio are set to launch the analysers and reagents in June 2024 after significant progress, including signing a supply and license agreement in March 2023. Notably, these analysers and reagents will be marketed under Agappe’s brand, marking Agappe as the first Indian company to offer a complete chemiluminescence solution with locally manufactured reagents.
Jain concludes, “The future holds immense potential for chemiluminescence analysers to revolutionize patient care and clinical outcomes across various medical domains, owing to their sensitivity and specificity. Continued advancements in technology, supportive regulatory frameworks, and strategic collaborations between healthcare stakeholders will be pivotal in realising the full potential of CLIA analysers in India’s healthcare landscape.”